Side-by-side financials for CUE and LLY. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | CUE | LLY |
|---|---|---|
| Market cap | - | $1.067 T |
| US-listed rank | - | #11 |
| Revenue (latest FY) | $27.47M | $65.18B |
| Net income (latest FY) | -$26.60M | $20.64B |
| Net margin | -96.9% | 31.7% |
| P/E (trailing FY) | - | 51.7 |
| SEC filings | 496 | 989 |
In their latest fiscal years, Cue Biopharma, Inc. reported $27.47M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Cue Biopharma, Inc. and ELI LILLY & Co, or browse the full rankings.